1. 541. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment Naïve Patients: Week 48 Results in Subgroups Based on Baseline Viral Load, CD4+ Count, and WHO Clinical Staging. (26th November 2018) Authors: Spinner, Christoph D; Rashbaum, Bruce; Mcdonald, Cheryl; Mussini, Cristina; Luo, Donghan; Jezorwski, John; Brown, Kimberley; Wong, Eric Y Journal: Open forum infectious diseases Issue: Volume 5(2018)Supplement 1 Page Start: S201 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. (17th July 2018) Authors: Eron, Joseph J.; Orkin, Chloe; Gallant, Joel; Molina, Jean-Michel; Negredo, Eugenia; Antinori, Andrea; Mills, Anthony; Reynes, Jacques; Van Landuyt, Erika; Lathouwers, Erkki; Hufkens, Veerle; Jezorwski, John; Vanveggel, Simon; Opsomer, Magda Journal: AIDS Issue: Volume 32:Number 11(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study. Issue 1 (2nd January 2019) Authors: Rashbaum, Bruce; Spinner, Christoph D.; McDonald, Cheryl; Mussini, Cristina; Jezorwski, John; Luo, Donghan; Van Landuyt, Erika; Brown, Kimberley; Wong, Eric Y. Journal: HIV research & clinical practice Issue: Volume 20:Issue 1(2019) Page Start: 24 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril) When Administered Concomitantly With a Tetravalent Dengue Vaccine Candidate in Healthy Toddlers at 12–13 Months of Age in Colombia and Peru: A Randomized Trial. Issue 10 (October 2016) Authors: López, Pio; Lanata, Claudio F.; Zambrano, Betzana; Cortés, Margarita; Andrade, Teresa; Amemiya, Isabel; Terrones, Cynthia; Gil, Ana I.; Verastegui, Hector; Marquez, Viviana; Crevat, Denis; Jezorwski, John; Noriega, Fernando Journal: Pediatric infectious disease journal Issue: Volume 35:Issue 10(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Week 96 resistance analyses of the once‐daily, single‐tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV‐1 from the phase 3 randomized AMBER and EMERALD trials. Issue 6 (15th February 2021) Authors: Lathouwers, Erkki; Weinsteiger, Shirley; Baugh, Bryan; Ghys, Anne; Jezorwski, John; Mohsine, El Ghazi; Van Landuyt, Erika; De Meyer, Sandra Journal: Journal of medical virology Issue: Volume 93:Issue 6(2021) Page Start: 3985 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. (1st April 2020) Authors: Orkin, Chloe; Eron, Joseph J.; Rockstroh, Jürgen; Podzamczer, Daniel; Esser, Stefan; Vandekerckhove, Linos; Van Landuyt, Erika; Lathouwers, Erkki; Hufkens, Veerle; Jezorwski, John; Opsomer, Magda Journal: AIDS Issue: Volume 34:Number 5(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1. Issue 6 (1st February 2021) Authors: Huhn, Gregory D.; Wilkin, Aimee; Mussini, Cristina; Spinner, Christoph D.; Jezorwski, John; El Ghazi, Mohsine; Van Landuyt, Erika; Lathouwers, Erkki; Brown, Kimberley; Baugh, Bryan Journal: HIV research & clinical practice Issue: Volume 21:Issue 6(2020) Page Start: 151 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1. Issue 6 (1st February 2021) Authors: Huhn, Gregory D.; Wilkin, Aimee; Mussini, Cristina; Spinner, Christoph D.; Jezorwski, John; El Ghazi, Mohsine; Van Landuyt, Erika; Lathouwers, Erkki; Brown, Kimberley; Baugh, Bryan Journal: HIV research & clinical practice Issue: Volume 21:Issue 6(2020) Page Start: 151 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗